Other mRNA Vaccines in Development

mRNA technology is currently being studied for many different uses.

Table 1, mRNA Candidates in Development*

Indication	Number of Candidates and Development Phase
Cancer (multiple types and stages); includes immunooncology and personalized vaccines, and with chemotherapy	31 (Phase I) 2 (Phase I/II) 4 (Phase II)
Congestive heart failure	1 (Phase I)
CMV	1 (Phase III)
Epstein-Barr Virus (to prevent mononucleosis)	1 (Phase I)
G6Pase Glycogen Storage Disease Type 1a (GSD1a)	1 (Phase I)
HIV	3 (Phase I)
HSV-2	1 (Phase I)
Influenza (monovalent and quadrivalent)	5 (Phase I) 5 (Phase I/II) 3 (Phase III)
Malaria	1 (Phase I)
Methylmalonic Acidemia	1 (Phase I/II)
Myocardial ischemia	1 (Phase II)
Nipah Virus	1 (Phase I)
PCCA/PCCB Propionic acidemia (PA)	1 (Phase II)
RSV (pediatric)	1 (Phase I)
RSV (older adults)	1 (Phase III)
SARS-CoV-2	4 (Phase I) 7 (Phase II) 5 (Phase III)
Shingles	1 (Phase I/II)
TB	2 (Phase I)
Zika Virus	1 (Phase II)
Combination vaccines	
Influenza/RSV	1 (Phase I)
Influenza/SARS-CoV-2	1 (Phase I) 1 (Phase I/II)
Influenza/ RSV/SARS-CoV-2	1 (Phase I)
Pediatric influenza/ pneumonia	1 (Phase I)

